Medical devices, healthcare technology and the business of care
PMA approval · P050047

JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS

Allergan · Decision date Jun 2, 2006

MEDTECHLEDGER EXPLANATIONP050047

What did the FDA approve?

FDA PMA P050047 was approved for the JUVEDERM 24HV, JUVEDERM 30, and JUVEDERM 30HV gel implants. The record here names the approved product family and does not describe any change from a prior version, so the exact relationship to an original PMA beyond this approval entry is not stated in the supplied text.

The source statement gives the labeled injection plane, mid to deep dermis, and the stated purpose, correction of moderate to severe facial wrinkles and folds such as nasolabial folds. It does not provide supporting study results, device construction details, or any broader clinical claims beyond that reported indication.

FDA approval order statement

APPROVAL FOR THE JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS. THE DEVICE IS INDICATED FOR INJECTION INTO THE MID TO DEEP DERMIS FOR CORRECTION OF MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS (SUCH AS NASOLABIAL FOLDS).
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Jun 2, 2006

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P050047
Regulatory pathway
Premarket approval application
Applicant
Allergan
Product code
LMH
Decision code
APPR
Decision date
Jun 2, 2006
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Allergan
Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P050047 received

    Application receipt date recorded by FDA.

  2. P050047 · FDA decision

    APPR

  3. P050047/S106 · Related supplement

    Juvéderm Ultra XC; Juvéderm Ultra Plus XC

Timeline entries are records held by MedtechLedger for P050047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050047

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allergan

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2525 Dupont Dr., Irvine, CA, 92612

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records